Indoco announces the launch of Brinzolamide Ophthalmic Suspension 1% in the US market by Teva Pharmaceuticals

Indoco Remedies announces the launch of Brinzolamide Ophthalmic Suspension 1% in the United States, the first generic version of AZOPT® by Teva Pharmaceuticals. The product is developed and manufactured by Indoco Remedies Ltd. for TEVA at its facility in Goa.

The ANDA approved by the US Food and Drug Administration for Brinzolamide Ophthalmic Suspension 1%, is used to treat high pressure inside the eye due to ocular hypertension and open-angle glaucoma. Brinzolamide Ophthalmic Suspension 1% works by decreasing the amount of fluid within the eye.

The US market size of this product is $184 million, according to IQVIA data as of December, 2020.

Commenting on this achievement, Ms. Aditi Kare Panandikar, Managing Director - Indoco Remedies Ltd. said, "This first-to-market generic version of AZOPT® (Brinzolamide Ophthalmic Suspension 1%, developed by Indoco) in the U.S. brings in an enormous opportunity to Indoco to serve the patients with a generic option. It also provides us immense satisfaction to be part of the journey in developing and securing approval from the US regulators for such Complex Generic products (ophthalmic suspensions), ensuring access to affordable and quality medicines."

Ms. Panandikar also added, "Indoco is vertically integrated for Brinzolamide API (manufactured at Patalganga site), which gives an edge to ensure continuity in commercial supplies."

Shares of INDOCO REMEDIES LTD. was last trading in BSE at Rs.276.25 as compared to the previous close of Rs. 281.3. The total number of shares traded during the day was 6495 in over 319 trades.

The stock hit an intraday high of Rs. 284.9 and intraday low of 275.35. The net turnover during the day was Rs. 1814061.

Source : Equity Bulls

Keywords